PE
pembrolizumab (Keytruda)
Merck & Co. · PDCD1 · Monoclonal Antibodies
Status
✓ Approved
Indications
39 conditions
Clinical Trials
2546 total
Active Trials
1389 ongoing
Targets
PDCD1
What is pembrolizumab?
Last updated: February 2025pembrolizumab is a monoclonal antibodies developed by Merck & Co.. It is approved for therapeutic indications via injectable (others) or intravenous (iv).
Drug Profile
| Generic Name | pembrolizumab |
| Brand Names | Keytruda |
| Company | Merck & Co. |
| Drug Class | Monoclonal Antibodies, Antibody |
| Molecular Target | PDCD1 |
| Route | Injectable (Others), Intravenous (IV) |
| Status | Approved |
Sources: ClinicalTrials.gov, Merck & Co.
Mechanism of Action
Molecular Targets
pembrolizumab acts on 1 molecular target:
| PDCD1 | programmed cell death 1 (PD1, hPD-l) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Clinical Trials
There are currently 2546 clinical trials registered, with 1389 actively ongoing.
| Trial ID | Phase | Title | Status |
|---|---|---|---|
| NCT03899155 | Phase 2 | Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Tr | ● Recruiting |
| NCT04781088 | Phase 2 | Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent | ● Active Not Recruiting |
| NCT02298959 | Phase 1 | A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors | ● Active Not Recruiting |
| NCT03854474 | Phase 1 | A Pilot Study of Tazemetostat and Pembrolizumab (MK-3475) in Advanced Urothelial Carcinoma | ● Active Not Recruiting |
| NCT05186974 | Phase 2 | An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatm | ● Active Not Recruiting |
| NCT05353439 | Phase 1 | Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination With Topotecan and Pembro | ● Recruiting |
+2542 more trials available with free account
Sign up free to view all clinical trials →Analyze Full Trial DataNoah can compare efficacy across trials and generate reports.
Therapeutic Indications
pembrolizumab is developed for 39 unique indications across 2 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Bladder cancer | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Hodgkin's disease recurrent | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer stage IV | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Skin cancer | ✓ Approved |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Non-small cell lung cancer metastatic | ✓ Approved |
+34 more indications available with free account
Sign up free to view all indications →